Squarepoint’s BioCardia BCDA Stock Holding History

Squarepoint’s Portfolio BCDA Stock Details BCDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,130	Closed	-$204K	–	3221
2021 Q1	$204K	Buy	+3,130	New	+$196K	﹤0.01%	2688

Other funds holding BCDA

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Squarepoint's BCDA Position: Q2 2021 in Review

Squarepoint sold out of BioCardia (BCDA) in Q2 2021, closing a stake of 3,130 shares — an estimated $204K sold.

Squarepoint first reported a position in BCDA in Q1 2021 and held it in 1 quarter. The position peaked at $204K in Q1 2021. 20 funds tracked by Wall St. Rank hold BCDA as of Q2 2021.

Squarepoint reported no remaining BioCardia position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 3,130 BioCardia shares in Q2 2021, an estimated $204K.
Squarepoint first reported a position in BioCardia in Q1 2021 and held it in 1 quarter.
Squarepoint's BioCardia position peaked at $204K in Q1 2021.
20 funds tracked by Wall St. Rank held BioCardia as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.